Where are ADCs heading? Lessons from the past year and priorities for the next

Tuesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Where are ADCs heading? Lessons from the past year and priorities for the next

How far did antibody-drug conjugates (ADCs) advance in 2026, and what will that progress mean for the field in 2027? In this webinar, the expert panel will review the year’s defining scientific, clinical, regulatory, and commercial milestones.

The speakers will then share their outlook for 2027 from each of these perspectives, including the opportunities and open questions they expect to shape ADCs and wider bioconjugate formats. Attendees will gain a clear view of which 2026 trends are likely to carry forward, where the field still faces scientific, clinical, and regulatory hurdles, and what the panel hopes to see in the year ahead.

Attend this webinar to:

Review the year’s scientific shifts, from payload diversification beyond topoisomerase I inhibitors to dual-payload, bispecific, and conditionally active designs.
Understand what 2026’s approvals, Phase 3 readouts, and setbacks reveal about the field’s clinical trajectory, including the move into earlier lines of therapy and the evidence regulators now expect.
Gain perspective on the year’s dealmaking and manufacturing landscape.
Explore expert expectations for 2027, including conjugates moving beyond traditional ADCs, non-oncology therapeutic settings, the growing role of companion diagnostics, and evolving regulatory endpoints.

Will Olughu

Global CMC Lead at Ipsen

Will has extensive experience in developing biologics and ADCs, providing strategic leadership across CMC, pharmaceutical development, technology transfer, manufacturing, and regulatory activities, while supporting the advancement of innovative therapeutics from early development through clinical milestones. With a particular interest in translating novel therapeutic modalities into scalable, commercially viable medicines, Will has led cross-functional collaborations spanning industry, academia, and external partners.

He is an active leader within the IChemE Biochemical Engineering Special Interest Group (BESIG), where he promotes knowledge exchange and innovation across the bioprocessing and bioconjugation communities. His interests include ADC development, CMC strategy, emerging bioconjugation technologies, and integrating scientific innovation with robust product development to improve patient outcomes.

Roy D. Baynes, MD, PhD

Executive Vice President, Chief Medical Officer at Eikon Therapeutics, Inc.

Roy Baynes, MD, PhD, currently serves as Executive Vice President and Chief Medical Officer of Eikon Therapeutics, Inc. a publicly traded biotechnology company. Prior to Eikon Therapeutics, Dr Baynes served as chief medical officer as well as senior vice president and head of global clinical development at Merck and Co, Inc, where he helped Merck become a leading oncology and global healthcare company. Dr Baynes also previously served as senior vice president of oncology, inflammation and respiratory therapeutics at Gilead Sciences, Inc., which was preceded by his service at Amgen, Inc. as vice president of global clinical development and therapeutic area head for hematology/oncology.

Before joining Amgen, Dr Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center, at Wayne State University. He received his medical degree and doctorate in philosophy from the University of the Witwatersrand in South Africa and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital. Dr Baynes has received innumerable awards for his activities as a physician/scientist, and currently serves on the board of directors at Natera, Inc., Travere Therapeutics, Inc., CatalYm GmbH, Nurix Inc., Aardvark Therapeutics Inc., and Adcendo ApS and is a compensated advisor to Decheng Capital, CatalYm GmbH and Adcendo ApS.

In 26 Days

You have registered for this webinar